Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor

Immune checkpoint inhibitors have shown anti-tumour activity in cancers such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma, colorectal cancer, and Hodgkin's lymphoma. Though immune checkpoint inhibitors have revolutionized the treatment and prognosis of som...

Full description

Bibliographic Details
Main Author: Rocha, Marta (author)
Other Authors: Correia de Sousa, João (author), Salgado, Marta (author), Araujo, A. (author), Pedroto, I. (author)
Format: article
Language:eng
Published: 2020
Subjects:
Colitis
Diarrhoea
Immune checkpoint inhibitor
Immune-related adverse event
Inibidores dos “checkpoint” imunológicos
Colite
Diarreia
Online Access:http://hdl.handle.net/10400.16/2389
Country:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2389

Internet

http://hdl.handle.net/10400.16/2389

Similar Items